AKT1	serine-threonine protein kinase
Akt	protein kinase B
ALL	acute lymphoblastic leukemia
AML	acute myeloid leukemia
B-ALL	B-cell acute lymphoblastic leukemia
BCL-2	B-cell lymphoma 2
BCL-XL	B-cell lymphoma-extra large
BCP-ALL	B-cell precursor acute lymphoblastic leukemia
CNS	central nervous system
COG	The Children’s Oncology Group
CRT	cranial radiotherapy
CR2	second complete remission
DFS	disease-free survival
DLBCL	diffuse large B-cell lymphoma
EGIL	The European Group for the Immunologic Classification
EFS	event-free survival
ETP-ALL	early T-cell precursor ALL
FBXW7	F-Box And WD Repeat Domain Containing 7
FCM	flow cytometry
FDA	Food and Drug Administration
GSI	γ-secretase inhibitors
HR	high risk
HSCT	hematopoietic stem-cell transplantation
IL7R	interleukin-7 receptor
JAK 1	janus kinase 1
LBL	acute lymphoblastic lymphoma
MAPK	mitogen-activated protein kinases
MRD	minimal residual disease
mTOR	mechanistic target of rapamycin
MTX	methotrexate
OS	overall survival
PCR	polymerase chain reaction
PDX	patient-derived xenografts
PIK3	phosphoinositide 3-kinase
SERCA	sarco/endoplasmic reticulum Ca2+-ATPase
SR	standard risk
STAT	signal transducer and activator of transcription
T-ALL	T-cell acute lymphoblastic leukemia
TLX1/3	T-cell leukemia homeobox protein ⅓
TP	time point
WBC	white blood cell
T-ALL	T-cell acute lymphoblastic leukemiatime point
TLX1/3	T-cell leukemia homeobox protein ⅓
TP	time point
WBC	white blood cell